Stournaras Evangelos, Neokosmidis Georgios, Stogiannou Dimitrios, Protopapas Andreas, Tziomalos Konstantinos
First Propaedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.
Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1277-1282. doi: 10.1097/MEG.0000000000001254.
Hepatocellular carcinoma (HCC) is a major complication of chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Accumulating data suggest that antiviral treatment in both CHB and CHC reduces the incidence of HCC. Evidence is more consistent for interferon-based treatment in both CHB and CHC and for lamivudine in patients with CHB. However, more limited data suggest that other nucleos(t)ide analogues might also reduce the risk of HCC. In contrast, conflicting data have been reported on the effects of direct-acting antivirals on the incidence of HCC.
肝细胞癌（HCC）是慢性乙型肝炎（CHB）和慢性丙型肝炎（CHC）的主要并发症。越来越多的数据表明，CHB和CHC的抗病毒治疗均可降低HCC的发生率。CHB和CHC基于干扰素的治疗以及CHB患者使用拉米夫定的证据更为一致。然而，数据较为有限，提示其他核苷（酸）类似物可能也会降低HCC风险。相比之下，关于直接抗病毒药物对HCC发生率的影响，已报道了相互矛盾的数据。
